Abstract
There is an unmet need for new approaches to treat prostate cancer beyond hormonal deprivation and chemotherapy. Using immunotherapy to focus immune responses on prostate cancer antigens appears to be a valid therapeutic approach. Several immunotherapeutic agents are being developed employing a variety of approaches. In recent years, Listeria monocytogenes (Lm)-LLO immunotherapy has been well tolerated in early clinical studies and is currently being evaluated in the clinic for HPV-associated dysplasia and malignancies such as recurrent/refractory cervical cancer, cervical intraepithelial neoplasia (CIN) 2/3, and head and neck cancer. Lm is a strong stimulator of both innate and cellular immune responses due to its unique life-cycle. Attenuated Listeria-based Lm-LLO immunotherapy secreting human prostate specific antigen (PSA) (ADXS31-142) has been shown to cause the therapeutic regression of PSA-expressing tumors in mouse models. The therapeutic effect of ADXSD31-142 on tumor regression is associated with the generation of PSAspecific T cells and subsequently, their infiltration in the tumor microenvironment, accompanied by the reduction of regulatory T cells (CD4+CD25+Foxp3+) within the tumors. Further development is underway to advance ADXS31-142 Lm- LLO immunotherapy into the clinic for the treatment of castration resistant prostate cancer.
Keywords: ADXS-PSA, Antigen-adjuvant fusion protein, Immunotherapy, Listeria monocytogenes, Lm-LLO, listeriolysin O, prostate cancer vaccine
Current Cancer Therapy Reviews
Title:Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Volume: 8 Issue: 4
Author(s): Anu Wallecha, Robert Petit, Chris French and John Rothman
Affiliation:
Keywords: ADXS-PSA, Antigen-adjuvant fusion protein, Immunotherapy, Listeria monocytogenes, Lm-LLO, listeriolysin O, prostate cancer vaccine
Abstract: There is an unmet need for new approaches to treat prostate cancer beyond hormonal deprivation and chemotherapy. Using immunotherapy to focus immune responses on prostate cancer antigens appears to be a valid therapeutic approach. Several immunotherapeutic agents are being developed employing a variety of approaches. In recent years, Listeria monocytogenes (Lm)-LLO immunotherapy has been well tolerated in early clinical studies and is currently being evaluated in the clinic for HPV-associated dysplasia and malignancies such as recurrent/refractory cervical cancer, cervical intraepithelial neoplasia (CIN) 2/3, and head and neck cancer. Lm is a strong stimulator of both innate and cellular immune responses due to its unique life-cycle. Attenuated Listeria-based Lm-LLO immunotherapy secreting human prostate specific antigen (PSA) (ADXS31-142) has been shown to cause the therapeutic regression of PSA-expressing tumors in mouse models. The therapeutic effect of ADXSD31-142 on tumor regression is associated with the generation of PSAspecific T cells and subsequently, their infiltration in the tumor microenvironment, accompanied by the reduction of regulatory T cells (CD4+CD25+Foxp3+) within the tumors. Further development is underway to advance ADXS31-142 Lm- LLO immunotherapy into the clinic for the treatment of castration resistant prostate cancer.
Export Options
About this article
Cite this article as:
Wallecha Anu, Petit Robert, French Chris and Rothman John, Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer, Current Cancer Therapy Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/1573394711208040254
DOI https://dx.doi.org/10.2174/1573394711208040254 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Systematic in-silico Analysis of Helicobacter pylori Pathogenic Islands for Identification of Novel Drug Target Candidates
Current Genomics Multifunctional Liquid Crystal Nanoparticles for Cancer Therapy
Current Nanomaterials Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Receptor-Independent Effects of Endocannabinoids on Ion Channels
Current Pharmaceutical Design Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer
Current Gene Therapy Editorial: [Hot Topic: Use of Microbicides to Prevent HIV Sexual Transmission (Guest Editor: Miguel E. Quinones-Mateu)]
Current HIV Research The Dynamics of the Hypothalamic-Pituitary-Ovarian Axis, ReproductivePerformance and Sexuality Following Bariatric Surgery
Current Women`s Health Reviews A Brief Review of circRNA Biogenesis, Detection, and Function
Current Genomics Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Chemistry of Bis-Spiroacetal Systems: Natural Products, Synthesis and Stereochemistry
Current Organic Chemistry MicroRNAs in Human Virus Genomes: Helping Hands for Viral Infection
MicroRNA Plasma-Free Amino Acid Profiling of Nasal Polyposis Patients
Combinatorial Chemistry & High Throughput Screening From HPV Infection to Oncogenesis: A Brief Review of the Complex Immunobiological Events
Current Cancer Therapy Reviews The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets Recent Developments in the Applications of Palladium Complexes Bearing N-Heterocyclic Carbene Ligands
Current Organic Chemistry Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery Cytotoxicity and Toxicological Studies of <i>Artocarpus altilis</i> Extracts, Inducing Apoptosis and Cell Cycle Arrest via <i>CASPASE-3</i> and <i>CASPASE-8</i> Pathways against Human Breast MCF-7 Cells
Combinatorial Chemistry & High Throughput Screening Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Occurrence and Severity of Adverse Reactions of Immune Checkpoint Inhibitors (PD-1 and PD L1) Based on Mordovian Dispensary Data Analysis
Current Cancer Therapy Reviews Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design